MRNS - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals Inc. (MRNS) | Benzinga
LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 5, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ:MRNS) securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
If you suffered a loss on your Marinus investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Marinus-Pharmaceuticals-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On April 15, 2024, Marinus disclosed that its Phase 3 RAISE trial for the treatment of refractory status epilepticus (RSE) had not met early stopping criteria and that the Company would be "evaluating potential cost-saving strategies." On this news, Marinus' stock price fell $6.22, ...
MRNS)>Full story available on Benzinga.com